Department of Neurology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
Department of Neurology, The Eighth Affiliated Hospital, SunYat-Sen University, Shenzhen, 528406, China.
J Neurol. 2024 May;271(5):2573-2581. doi: 10.1007/s00415-024-12197-4. Epub 2024 Feb 8.
Whether statin treatment is effective in retarding the progression of radiation-induced carotid stenosis (RICS) in head and neck cancer (HNC) survivors has not been well studied. The purpose of this study was to assess the association of statin treatment with RICS progression rate in HNC survivors after radiotherapy.
We conducted a retrospective cohort study at Sun Yat-sen Memorial Hospital, Sun Yat-sen University in Guangzhou, China. Between January 2010 and December 2021, we screened HNC survivors whose carotid ultrasound scans had shown stenosis of the common and/or internal carotid arteries. The primary outcome was the RICS progression rate. We compared eligible patients treated with statins with those who did not in multivariable Cox regression models.
A total of 200 patients were included in this study, of whom 108 received statin treatment and 92 did not. Over a mean follow-up time of 1.5 years, 56 (28.0%) patients showed RICS progression, 24 (42.9%) and 32 (57.1%) in the statin and control groups, respectively. The statin group showed less RICS progression than the control group (adjusted-HR 0.49, 95% CI 0.30-0.80, P = 0.005). In the subgroup analysis, there was no significant interaction in the effect of statins on lowering RICS progression rate in the subgroups stratified by baseline low-density lipoprotein cholesterol (LDL-C) levels (P for interaction = 0.53) or baseline degrees of stenosis (P for interaction = 0.50).
Statin treatment was associated with a lower risk of RICS progression in patients with HNC after radiotherapy, regardless of baseline LDL-C level and baseline stenosis degrees.
他汀类药物治疗是否能延缓头颈部癌症(HNC)幸存者的放射性颈动脉狭窄(RICS)进展尚未得到很好的研究。本研究旨在评估他汀类药物治疗与放疗后 HNC 幸存者 RICS 进展率的相关性。
我们在中国广州中山大学孙逸仙纪念医院进行了一项回顾性队列研究。在 2010 年 1 月至 2021 年 12 月期间,我们筛选了颈动脉超声显示颈总动脉和/或颈内动脉狭窄的 HNC 幸存者。主要结局是 RICS 进展率。我们在多变量 Cox 回归模型中比较了接受他汀类药物治疗和未接受他汀类药物治疗的合格患者。
本研究共纳入 200 例患者,其中 108 例接受他汀类药物治疗,92 例未接受。在平均 1.5 年的随访期间,56 例(28.0%)患者出现 RICS 进展,他汀组和对照组分别为 24 例(42.9%)和 32 例(57.1%)。他汀组的 RICS 进展率低于对照组(调整后的 HR 0.49,95%CI 0.30-0.80,P=0.005)。在亚组分析中,根据基线低密度脂蛋白胆固醇(LDL-C)水平(P 交互=0.53)或基线狭窄程度(P 交互=0.50)分层,他汀类药物对降低 RICS 进展率的效果在亚组之间没有显著的交互作用。
他汀类药物治疗与放疗后 HNC 患者的 RICS 进展风险降低相关,无论基线 LDL-C 水平和基线狭窄程度如何。